Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 10, 2015System Includes First Directional Lead with Current Steering and Expanded Programming FlexibilityBoston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
Sep 2, 2015Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Morgan Stanley Global Healthcare Conference on September 17, in New York City. Mike Mahoney, chief executive...
- Aug 26, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Wells Fargo Healthcare Conference on September 9 in Boston, MA. Mike Mahoney, chief executive officer, and Dan...
Aug 24, 2015Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systemsBoston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...
Aug 19, 2015U.S. Launch Underway for Therapy Designed to Treat Peripheral Artery DiseaseBoston Scientific Corporation (NYSE: BSX) has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent System, an advanced treatment option for patients...
- Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase American Medical Systems' (AMS) Men's...
- Aug 3, 2015Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions
Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related...
Jul 23, 2015Boston Scientific Corporation (NYSE: BSX) generated sales of $1.843 billion during the second quarter ended June 30, 2015, compared to the company's guidance range for the quarter of $1.800 to...
Jul 22, 2015First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller VentriclesMARLBOROUGH, Mass. (July 22, 2015) – Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new and enhanced version of the Safari...
- Jul 20, 2015First Patients Enrolled in the FAST Feasibility Study
Boston Scientific (NYSE: BSX) has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective,...